COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01654822
Recruitment Status : Unknown
Verified November 2012 by Cesa Projects International.
Recruitment status was:  Active, not recruiting
First Posted : August 1, 2012
Last Update Posted : November 9, 2012
Information provided by (Responsible Party):
Cesa Projects International

Brief Summary:

This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV) infection.

  • Primary endpoint: significant drop in viral load AV2-DM versus placebo
  • Secondary endpoint:the number of patients with adverse events

Condition or disease Intervention/treatment Phase
Genital Human Papilloma Virus Infection Drug: topical application cervical spray Drug: topical spray on the cervix Procedure: cervical swab with Cervex-Brush-Combi at T0 Procedure: cervical swab with Cervex-Brush-Combi at T1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load
Study Start Date : August 2012
Estimated Primary Completion Date : December 2012
Estimated Study Completion Date : January 2013

Arm Intervention/treatment
Placebo Comparator: olive oil with 10% d-limonene
Topical spray one-time administration 2 puffs of 100µl
Drug: topical spray on the cervix
one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix

Procedure: cervical swab with Cervex-Brush-Combi at T0
Procedure: cervical swab with Cervex-Brush-Combi at T1
Experimental: AV2-DM antiviral spray
Topical spray one-time application 2 puffs of 100µl
Drug: topical application cervical spray
one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix

Procedure: cervical swab with Cervex-Brush-Combi at T0
Procedure: cervical swab with Cervex-Brush-Combi at T1

Primary Outcome Measures :
  1. Efficacy comparison number of patients with drop (min 2 Log units) in HPV specific viral load AV2-DM versus placebo [ Time Frame: 90 days ]

Secondary Outcome Measures :
  1. number of adverse vents AV2-DM versus placebo [ Time Frame: 90 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women between 25 and 40 years
  2. Patient has been recently (up to 6 months) Quantitatively (Viral Load) and Qualitatively (HPV types) diagnosed with HPV.
  3. Ability and willingness to participate in the study.
  4. Subject agrees to refrain from using prescription or supplemental antiviral medications without obtaining permission of the Treating Doctor.
  5. Voluntary written informed consent.

Exclusion Criteria:

  1. Subject has been vaccinated against HPV
  2. Interval between a delivery and T0 is less than 3 months
  3. Subject has a gynecologic surgical intervention between T0 and T1
  4. Subject is diagnosed HPV negative at T0
  5. Subject has a (adeno)carcinoma in situ.
  6. Females with child bearing potential who are not using a reliable, medically accepted method of birth control
  7. Pregnant or breast-feeding female, or women planning to become pregnant during the trial.
  8. Medical history of immunosuppression by radiotherapy, chemotherapy, immuno-modulatory drugs, or HIV.
  9. Participation to another clinical trial concerning HPV infections within 6 months before the application of AV2-DM antiviral spray.
  10. Medical history of any severe diseases like hepatitis, renal or liver dysfunction, car-diovascular, gastrointestinal, malignant tumor(s), or psychiatric disorders etc., which might influence the assessments or conduct of the trial by the discretion of the investigator.
  11. Intake or application of antivirals or other prohibited concomitant medication within 30 days prior to application of AV2, or patients who plan to take such drugs during the trial.
  12. Known or suspected allergic or adverse response to the investigational product AV2-DM Antiviral spray, it's components, olive oil or d-limonene.
  13. Inability to follow the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01654822

Layout table for location information
Labo Riatol
Antwerpen, Belgium, 2020
Sponsors and Collaborators
Cesa Projects International
Layout table for additonal information
Responsible Party: Cesa Projects International Identifier: NCT01654822    
Other Study ID Numbers: AV2-HPV-001
First Posted: August 1, 2012    Key Record Dates
Last Update Posted: November 9, 2012
Last Verified: November 2012
Keywords provided by Cesa Projects International:
Additional relevant MeSH terms:
Layout table for MeSH terms
Papillomavirus Infections
Virus Diseases
Neoplasms, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
DNA Virus Infections
Tumor Virus Infections